Radiother Oncol 2020 Jul 31
An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.
ABSTRACT
Our study is the first to report an especially high rate of grade 2 or worse radiation pneumonitis in patients treated with thoracic radiotherapy and simultaneous Osimertinib, despite total lung V5, V20 and MLD seeming unlikely to induce radiation pneumonitis.
Related Questions
Does the site of treatment factor into your decision?
New comment by Medical Oncologist at MD Anderson Cancer Center at Cooper - Camden ( February 20, 2024)
Any reason to hold osimertinib if RT is given to painful bony metastasis?